
Transgene Announces Upcoming Investor Meetings
Regulatory News:
Transgene (Paris:TNG) today announces that Management will participate in the upcoming investor events set out below.
Transgene will meet institutional investors at the LifeSci Advisors Corporate Access Event from January 7 to 9, 2019, in San Francisco, USA, concurrent with the J.P. Morgan Healthcare conference.
The Company will also attend:
- Oddo Forum: January 10 & 11, 2019 – Lyon, France
- Biomed Event: January 22, 2019 – Paris, France
- Degroof Petercam Healthcare Seminar:January 31, 2019 – Brussels, Belgium
- HC Wainwright Conference: April 8 & 9, 2019 – London, UK
- Kempen Life Sciences Conference: April 16 & 17, 2019 – Amsterdam, Netherlands
- Small Cap Event: April 16 & 17, 2019 – Paris, France
About Transgene
Transgene (Euronext: TNG) is a
publicly traded French biotechnology company focused on designing and
developing targeted immunotherapies for the treatment of cancer and
infectious diseases. Transgene’s programs utilize viral vector
technology with the goal of indirectly or directly killing infected or
cancerous cells. The Company’s lead clinical-stage programs are: TG4010,
a therapeutic vaccine against non-small cell lung cancer, Pexa-Vec, an
oncolytic virus against liver cancer, and TG4001, a therapeutic vaccine
against HPV-positive head and neck cancers. The Company has several
other programs in clinical development, including TG1050 (a therapeutic
vaccine for the treatment of chronic hepatitis B) and TG6002 (an
oncolytic virus for the treatment of solid tumors).
With its
proprietary Invir.IO™, Transgene builds on its expertise in viral
vectors engineering to design a new generation of multifunctional
oncolytic viruses.
myvac™, an individualized MVA-based
immunotherapy platform designed to integrate neoantigens, completes this
innovative research portfolio.
Additional information about
Transgene is available at www.transgene.fr.
Follow
us on Twitter: @TransgeneSA
View source version on businesswire.com: https://www.businesswire.com/news/home/20181205005513/en/
Editor Details
-
Company:
- Business Wire
- Website: